General Oncology
Massachusetts-based General Oncology develops treatments for metastatic cancers, currently conducting a clinical trial for BRCA-related pancreatic cancer.
Founded
2015Massachusetts-based General Oncology develops treatments for metastatic cancers, currently conducting a clinical trial for BRCA-related pancreatic cancer.
Founded in Burlington, Massachusetts, General Oncology is a pharmaceutical company dedicated to developing treatments for metastatic cancers. Their core mission is to cure metastatic cancer through innovative drug development and clinical trials. The company’s pipeline includes both clinical and preclinical studies targeting a variety of solid tumors and blood cancers. Currently, they are conducting a clinical trial (Clinical Trial GO-1) for an investigational treatment for BRCA-related metastatic pancreatic cancer, utilizing a combination of chemotherapy and stem cell support.
General Oncology has attracted notable attention in the medical community, enrolling multiple patients in their groundbreaking clinical trials. Their work has garnered interest from key investors and stakeholders in the healthcare sector. The company’s significant achievement includes the advancement of their investigational treatment to the clinical trial phase, demonstrating potential in treating BRCA-related metastatic pancreatic cancer. Through their focused efforts, General Oncology aims to make a substantial impact on cancer treatment and patient outcomes.
Companies similar to General Oncology include G1 Therapeutics, Oncology Honduras, Champions Oncology and D2G Oncology.
General Oncology was founded in 2015.
General Oncology's headquarters is located in Burlington, MA, US.
General Oncology's most recent funding round was for $6M (USD) in June 2019.
As of Jun 25, 2019, General Oncology has raised a total of $6M (USD).
General Oncology has 7 employees as of Feb 5, 2024.
Champions Oncology
